Cladribine shows promise in patients with difficult-to-treat myasthenia gravis


Play all audios:

Access through your institution Buy or subscribe A new open-label study published in the _European Journal of Neurology_ has provided evidence of efficacy of cladribine in difficult-to-treat


cases of myasthenia gravis (MG) — a rare autoimmune neuromuscular disorder. Cladribine is an immunomodulatory drug that has been approved in some countries for the treatment of


relapsing–remitting multiple sclerosis. The study included 13 patients with MG who had shown an insufficient response to standard therapy for this condition. Following 6 months of treatment


with cladribine, 11 of the participants demonstrated significant clinical improvement, defined as a reduction of ≥3 points on the Myasthenia Gravis Composite scale. The investigators


conclude that cladribine is a promising treatment for MG but additional studies are needed to refine the dosing regime and to determine long-term efficacy and safety. This is a preview of


subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value


online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more


Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:


* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Rejdak, K. et al. Cladribine in myasthenia gravis: a pilot


open-label study. _Eur. J. Neurol._ https://doi.org/10.1111/ene.14124 (2019) Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews


Neurology http://www.nature.com/nrneurol/ Heather Wood Authors * Heather Wood View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR


Correspondence to Heather Wood. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wood, H. Cladribine shows promise in patients with difficult-to-treat


myasthenia gravis. _Nat Rev Neurol_ 16, 2 (2020). https://doi.org/10.1038/s41582-019-0292-z Download citation * Published: 21 November 2019 * Issue Date: January 2020 * DOI:


https://doi.org/10.1038/s41582-019-0292-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative